Skip to content
WyteRock E-Books

WyteRock Blog

IVDR in-house tests: what European laboratories must do, and by when

WyteRock Global · 2026-10-30

Most conditions of the IVDR health-institution exemption already apply. One, the "no equivalent CE-marked test" justification, is deferred until 31 December 2030; a pending Commission proposal would remove it altogether.

Since 26 May 2022, a test that a hospital or public-health laboratory designs, builds or modifies for its own patients has been an in vitro diagnostic medical device under Regulation (EU) 2017/746 (the IVDR). It does not need a CE mark, but it is not unregulated either. Article 5(5) grants a conditional exemption: with the exception of the relevant general safety and performance requirements (GSPR) in Annex I, the Regulation's requirements do not apply to devices manufactured and used only within health institutions established in the Union, provided a list of conditions is met. The exemption does not apply to devices manufactured on an industrial scale.

Who qualifies

A "health institution" is an organisation whose primary purpose is the care or treatment of patients or the promotion of public health (Article 2(29)). MDCG 2023-1 (January 2023) confirms that this includes laboratories that do not treat patients directly, and clarifies three points:

  • Legal entity. The test must be made and used within one legal entity. Several hospitals under one organiser can be one entity; national authorities may define the term.
  • Sharing. Written protocols, specimens and results may be shared; a device used outside the legal entity cannot be in-house.
  • Repurposing. Where an institution gives a research-use-only product a diagnostic purpose, or changes the intended purpose of a CE-marked device, Article 5(5) applies.

The conditions

Article 5(5) sets nine conditions, (a) to (i):

  • (a) the devices are not transferred to another legal entity;
  • (b) manufacture and use occur under an appropriate quality management system;
  • (c) the laboratory complies with EN ISO 15189 or, where applicable, national provisions, including national accreditation rules;
  • (d) the institution justifies in its documentation that the target patient group's specific needs cannot be met, or cannot be met at the appropriate level of performance, by an equivalent device available on the market;
  • (e) it provides information on use, including the justification for manufacture, modification and use, to its competent authority on request;
  • (f) it publishes a declaration;
  • (g) for class D devices, it draws up documentation on the facility, the manufacturing process, design and performance data and intended purpose, sufficient for the competent authority to verify GSPR compliance (Member States may extend this to classes A to C);
  • (h) it ensures that all devices are manufactured in accordance with that documentation;
  • (i) it reviews experience from clinical use and takes all necessary corrective actions.

Member States may also request further information and may restrict the manufacture and use of specific types of in-house device.

The timetable

Regulation (EU) 2022/112 staggered these conditions, and Regulation (EU) 2024/1860 moved one date again:

From What applies
26 May 2022 Annex I GSPR; condition (a); exclusion of industrial-scale manufacture
26 May 2024 Conditions (b), (c) and (e) to (i)
31 December 2030 Condition (d), the justification (originally 26 May 2028 under 2022/112; moved by 2024/1860)

In other words, every condition except the justification is already in force. The Commission's Q&A on Regulation 2024/1860 explains the deferral: laboratories need a complete view of the CE-marked tests on the market, so the obligation applies one year after the last IVDR transitional period ends (31 December 2029 for class B and sterile class A legacy devices).

Preparing the justification

MDCG 2023-1 expects a documented search for equivalent CE-marked devices available in the relevant Member State before first manufacture, with periodic review. Non-equivalence may rest on intended purpose, patient group, specimen type, principle of operation or critical performance. The guidance cites oestradiol in women on aromatase inhibitors, where immunoassays lack the sensitivity that LC-MS provides. If an equivalent CE-marked test later appears, the original justification stands, but the institution should review it and, where the new test meets the need, begin a transition.

The public declaration and documentation

The declaration under condition (f) must name the institution and its address, identify the devices, and state that they meet Annex I, justifying any requirement not fully met. MDCG 2023-1 Annex A offers a template; national rules may fix format, language and place of publication. The guidance also notes that EN ISO 15189 alone is not an adequate quality system for manufacture, which lies outside that standard's scope. IVDR Annex II can structure the documentation.

The December 2025 proposal

On 16 December 2025 the Commission adopted COM(2025) 1023, a proposal to simplify the MDR and IVDR (procedure 2025/0404(COD)). For in-house IVDs it would delete condition (d); permit transfer to another health institution in the justified interest of public health or patient safety, or for a public-health emergency; let ISO 15189-accredited laboratories declare accreditation instead of GSPR compliance and exempt them from the class D documentation duty; delete condition (h); and extend the exemption to laboratories making tests used only in clinical trials under Regulation (EU) No 536/2014.

This is a proposal, not law. As of October 2026 it is before the Parliament and the Council; Sidley expects a committee vote in early 2027 and a final text no earlier than late 2027. Until adoption, the current Article 5(5) and its timetable apply.

Checklist: six steps for a laboratory

  1. Inventory every in-house test, including modified CE-marked kits and RUO products given a diagnostic purpose, and classify each under IVDR Annex VIII.
  2. Confirm the legal entity within which each test is made and used, and stop any transfer to other entities.
  3. Close quality-system gaps now: conditions (b), (c) and (e) to (i) have applied since 26 May 2024. Add test manufacture, design control and risk management to the ISO 15189 system.
  4. Publish the declaration under condition (f), checking national requirements for format and language.
  5. Complete class D documentation, and check whether your Member State extends the duty to classes A to C.
  6. Start the market search for equivalent CE-marked tests, document it, and set a review cycle, so the justification is ready by 31 December 2030 if the proposal does not remove it.

Alex Mansour is CEO of WyteRock Global, a France-based life-sciences advisory firm that supports laboratories and manufacturers on EU MDR and IVDR compliance.

Sources

  1. Regulation (EU) 2017/746 on in vitro diagnostic medical devices, consolidated text (Articles 2(29), 5(5), 113(3)). EUR-Lex: https://eur-lex.europa.eu/eli/reg/2017/746/oj/eng
  2. Regulation (EU) 2022/112 amending Regulation (EU) 2017/746 as regards transitional provisions and the deferred application of conditions for in-house devices (OJ L 19, 28.1.2022). EUR-Lex: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex:32022R0112
  3. Regulation (EU) 2024/1860 of 13 June 2024 (gradual roll-out of Eudamed, interruption of supply, IVD transitional provisions); in force 9 July 2024. EUR-Lex: https://eur-lex.europa.eu/eli/reg/2024/1860/oj/eng
  4. European Commission, Q&A on the extension of the IVDR transitional periods (Regulation (EU) 2024/1860), Part E, question 18, and Appendix. https://health.ec.europa.eu/document/download/dfd7a1c6-f319-4682-9bac-77bef1165818_en?filename=mdr_qna-ext-ivdr.pdf
  5. MDCG 2023-1, Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746 (January 2023). https://health.ec.europa.eu/system/files/2023-01/mdcg_2023-1_en.pdf
  6. European Commission, COM(2025) 1023 final, 2025/0404(COD), Proposal amending Regulations (EU) 2017/745 and (EU) 2017/746 (16 December 2025): recitals 12–13 and Article 2, point (5). https://health.ec.europa.eu/document/download/25e7ea7c-cab3-40cf-86d9-d11f5e7744d8_en?filename=md_com_2025-1023_act_en.pdf
  7. Sidley Austin, "A More Competitive MedTech Landscape in the EU? What the MDR/IVDR Revision Could Mean" (16 October 2026), for legislative status. https://goodlifesci.sidley.com/2026/10/16/a-more-competitive-medtech-landscape-in-the-eu-what-the-mdr-ivdr-revision-could-mean-for-medtech-manufacturers-and-investors/
  8. European Commission, IVDR transitional provisions page. https://health.ec.europa.eu/medical-devices-vitro-diagnostics/transitional-provisions_en

Get new articles by email. Sign up for the newsletter or join the CentiAgent Club; members receive an alert for every new article.